Procept BioRobotics' (PRCT) estimate of its addressable market "is overly exaggerated," Spruce Point Capital Management said in a short report Thursday.
Spruce Point also said the company's claim that it will fundamentally change current benign prostatic hyperplasia protocols is "unrealistic, since there is no one-size-fits-all BPH treatment."
Procept BioRobotics didn't immediately respond to a request for comment from MT Newswires.
The company's shares were down 0.9% in recent trading.
Price: 77.64, Change: -0.67, Percent Change: -0.86